FDA nod for new Cushing's disease treatment

The US Food and Drug Administration on Friday approved Isturisa (osilodrostat) oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.

Developed by Swiss pharma giant Novartis (NOVN: VX), Isturisa is the first FDA-approved drug to directly address this cortisol overproduction by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis. Cushing’s disease is a rare disease in which the adrenal glands make too much of the cortisol hormone.

Licensed to Recordati